A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer

Science Translational Medicine

Volumn 8, Issue 320, 2016, Pages

  Whitley, Melodi Javid ^a   Cardona, Diana M ^a   Lazarides, Alexander L ^b   Spasojevic, Ivan ^a   Ferrer, Jorge M ^c   Cahill, Joan ^a   Lee, Chang Lung ^a   Snuderl, Matija ^d,g   Blazer, Dan G ^a   Hwang, E Shelley ^a   Greenup, Rachel A ^a   Mosca, Paul J ^a   Mito, Jeffrey K ^a   Cuneo, Kyle C ^a   Larrier, Nicole A ^a   O'Reilly, Erin K ^b   Riedel, Richard F ^a   Eward, William C ^a   Strasfeld, David B ^c   Fukumura, Dai ^d   Jain, Rakesh K ^d   Lee, W David ^c   Griffith, Linda G ^e   Bawendi, Moungi G ^f   Kirsch, David G ^a   Brigman, Brian E ^a   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Lumicell Inc   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e Massachusetts Institute of Technology   (United States)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; DRUG METABOLITE; LYSINE; PROTEASE ACTIVATED FLUORESCENT PROBE; PROTEINASE; UNCLASSIFIED DRUG; FLUORESCENT DYE; PEPTIDE HYDROLASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER MODEL; CANCER RECURRENCE; CELL LABELING; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG TISSUE LEVEL; DRUG TOLERABILITY; ENZYME ACTIVITY; EX VIVO STUDY; FEMALE; FLUORESCENCE ANALYSIS; FLUORESCENCE IMAGING SYSTEM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; SOLID TUMOR; ANIMAL; BREAST NEOPLASMS; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE MODEL; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; METABOLOME; NEOPLASMS; PROCEDURES; SARCOMA; TISSUE DISTRIBUTION;

ANIMALS; BREAST NEOPLASMS; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCENT DYES; HUMANS; INJECTIONS, INTRAVENOUS; METABOLOME; MICE; NEOPLASMS; PEPTIDE HYDROLASES; SARCOMA; TISSUE DISTRIBUTION;

EID: 84954509620     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aad0293     Document Type: Article

References (41)

1. P. W. Pisters, D. H. Leung, J. Woodruff, W. Shi, M. F. Brennan, Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J. Clin. Oncol. 14, 1679-1689 (1996).
2. B. Fisher, S. Anderson, J. Bryant, R. G. Margolese, M. Deutsch, E. R. Fisher, J.-H. Jeong, N. Wolmark, Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N. Engl. J. Med. 347, 1233-1241 (2002).
3. J. C. Yang, A. E. Chang, A. R. Baker, W. F. Sindelar, D. N. Danforth, S. L. Topalian, T. DeLaney, E. Glatstein, S. M. Steinberg, M. J. Merino, S. A. Rosenberg, Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J. Clin. Oncol. 16, 197-203 (1998).
4. M. S. Anscher, P. Jones, L. R. Prosnitz, W. Blackstock, M. Hebert, R. Reddick, A. Tucker, R. Dodge, G. Leight Jr., J. D. Iglehart, et al., Local failure and margin status in early-stage breast carcinoma treated with conservation surgery and radiation therapy. Ann. Surg. 218, 22-28 (1993).
5. J. C. Cendán, D. Coco, E. M. Copeland III, Accuracy of intraoperative frozen-section analysis of breast cancer lumpectomy-bed margins. J. Am. Coll. Surg. 201, 194-198 (2005).
6. S. Harmsen, R. Huang, M. A. Wall, H. Karabeber, J. M. Samii, M. Spaliviero, J. R. White, S. Monette, R. O'Connor, K. L. Pitter, S. A. Sastra, M. Saborowski, E. C. Holland, S. Singer, K. P. Olive, S. W. Lowe, R. G. Blasberg, M. F. Kircher, Surface-enhanced resonance Raman scattering nanostars for high-precision cancer imaging. Sci. Transl. Med. 7, 271ra7 (2015).
7. Y. Liu, J. R. Ashton, E. J. Moding, H. Yuan, J. K. Register, A. M. Fales, J. Choi, M. J. Whitley, X. Zhao, Y. Qi, Y. Ma, G. Vaidyanathan, M. R. Zalutsky, D. G. Kirsch, C. T. Badea, T. Vo-Dinh, A plasmonic gold nanostar theranostic probe for in vivo tumor imaging and photothermal therapy. Theranostics 5, 946-960 (2015).
8. Q. R. J. G. Tummers, F. P. R. Verbeek, B. E. Schaafsma, M. C. Boonstra, J. R. van der Vorst, G.-J. Liefers, C. J. H. van de Velde, J. V. Frangioni, A. L. Vahrmeijer, Real-time intraoperative detection of breast cancer using near-infrared fluorescence imaging and Methylene Blue. Eur. J. Surg. Oncol. 40, 850-858 (2014).
9. N. Kosaka, M. Mitsunaga, M. R. Longmire, P. L. Choyke, H. Kobayashi, Near infrared fluorescenceguided real-time endoscopic detection of peritoneal ovarian cancer nodules using intravenously injected indocyanine green. Int. J. Cancer 129, 1671-1677 (2011).
10. R. A. Sheth, R. S. Arellano, R. N. Uppot, A. E. Samir, L. Goyal, A. X. Zhu, D. A. Gervais, U. Mahmood, Prospective trial with optical molecular imaging for percutaneous interventions in focal hepatic lesions. Radiology 274, 917-926 (2015).
11. R. Weissleder, Molecular imaging in cancer. Science 312, 1168-1171 (2006).
12. G.M. vanDam,G. Themelis, L. M.A. Crane,N. J.Harlaar, R.G. Pleijhuis,W. Kelder, A. Sarantopoulos, J. S. de Jong, H. J. G. Arts, A. G. J. van der Zee, J. Bart, P. S. Low, V. Ntziachristos, Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-a targeting: First inhuman results. Nat. Med. 17, 1315-1319 (2011).
13. Y. Ardeshirpour, M. Hassan, R. Zielinski, J. A. Horton, J. Capala, A. H. Gandjbakhche, V. Chernomordik, In vivo assessment of HER2 receptor density in HER2-positive tumors by near-infrared imaging, using repeated injections of the fluorescent probe. Technol. Cancer Res. Treat. 13, 427-434 (2014).
14. R.Weissleder, C.-H. Tung, U. Mahmood, A. Bogdanov Jr., In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat. Biotechnol. 17, 375-378 (1999).
15. J. E. Koblinski, M. Ahram, B. F. Sloane, Unraveling the role of proteases in cancer. Clin. Chim. Acta 291, 113-135 (2000).
16. M. M. Mohamed, B. F. Sloane, Cysteine cathepsins: Multifunctional enzymes in cancer. Nat. Rev. Cancer 6, 764-775 (2006).
17. J. K. Mito, J. M. Ferrer, B. E. Brigman, C.-L. Lee, R. D. Dodd, W. C. Eward, L. F. Marshall, K. C. Cuneo, J. E. Carter, S. Ramasunder, Y. Kim, W. D. Lee, L. G. Griffith, M. G. Bawendi, D. G. Kirsch, Intraoperative detection and removal of microscopic residual sarcoma using wide-field imaging. Cancer 118, 5320-5330 (2012).
18. S. BartholfDeWitt, C. Eward,W. C. Eward, A. L. Lazarides,D.G. Kirsch,D. M. Cardona,B. E. Brigman, J.K.Mito, M. J.Whitley, J. M. Ferrer, D. B. Strasfeld, D. Lee, K. Concannon,G. Spodnick, E.Holmes, K. Miller, J. Berg, in The American College of Veterinary Surgeons 2014 Surgery Summitt (San Diego, California, 2014).
19. E. J. Freireich, E. A. Gehan, D. P. Rall, L. H. Schmidt, H. E. Skipper, Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. 50, 219-244 (1966).
20. B. O'Sullivan, A. M. Davis, R. Turcotte, R. Bell, C. Catton, P. Chabot, J. Wunder, R. Kandel, K. Goddard, A. Sadura, J. Pater, B. Zee, Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomised trial. Lancet 359, 2235-2241 (2002).
21. E. Segal, T. R. Prestwood, W. A. van der Linden, Y. Carmi, N. Bhattacharya, N. Withana, M. Verdoes, A. Habtezion, E. G. Engleman, M. Bogyo, Detection of intestinal cancer by local, topical application of a quenched fluorescence probe for cysteine cathepsins. Chem. Biol. 22, 148-158 (2015).
22. C. Bremer, C.-H. Tung, R. Weissleder, In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat. Med. 7, 743-748 (2001).
23. E. S. Olson, T. Jiang, T. A. Aguilera, Q. T. Nguyen, L. G. Ellies, M. Scadeng, R. Y. Tsien, Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc. Natl. Acad. Sci. U.S.A. 107, 4311-4316 (2010).
24. T. Quillard, K. Croce, F. A. Jaffer, R. Weissleder, P. Libby, Molecular imaging of macrophage protease activity in cardiovascular inflammation in vivo. Thromb. Haemost. 105, 828-836 (2011).
25. C. E. Lewis, J. W. Pollard, Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66, 605-612 (2006).
26. E. Y. Lin, A. V. Nguyen, R. G. Russell, J. W. Pollard, Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193, 727-740 (2001).
27. G. W. Caldwell, J. A. Masucci, Z. Yan, W. Hageman, Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vss and t1/2 be predicted from in-vivo rat data? Eur. J. Drug Metab. Pharmacokinet. 29, 133-143 (2004).
28. T. Kolokotrones, S. Van, E. J. Deeds, W. Fontana, Curvature in metabolic scaling. Nature 464, 753-756 (2010).
29. W. P. Caron, H. Clewell, R. Dedrick, R. K.Ramanathan, W. L. Davis, N. Yu, M. Tonda, J. H. Schellens, J. H. Beijnen, W. C. Zamboni, Allometric scaling of pegylated liposomal anticancer drugs.
30. W. D. Dupont, W. D. Plummer Jr., Power and sample size calculations. A review and computer program. Control. Clin. Trials 11, 116-128 (1990).
31. K. C. Cuneo, J. K. Mito, M. P. Javid, J. M. Ferrer, Y. Kim, W. D. Lee, M. G. Bawendi, B. E. Brigman, D. G. Kirsch, Imaging primary mouse sarcomas after radiation therapy using cathepsinactivatable fluorescent imaging agents. Int. J. Radiat. Oncol. Biol. Phys. 86, 136-142 (2013).
32. D. L. Taylor, Y.-l. Wang, Fluorescence microscopy of living cells in culture, in Methods in Cell Biology, L. Wilson, Ed. (Academic Press, San Diego, CA, 1989), vol. 29, pp. 1-328.
33. M. Sachdeva, J. K. Mito, C.-L. Lee, M. Zhang, Z. Li, R. D. Dodd, D. Cason, L. Luo, Y. Ma, D. Van Mater, R. Gladdy, D. C. Lev, D. M. Cardona, D. G. Kirsch, MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes. J. Clin. Invest. 124, 4305-4319 (2014).
34. E. L. Jackson, N. Willis, K. Mercer, R. T. Bronson, D. Crowley, R. Montoya, T. Jacks, D. A. Tuveson, Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243-3248 (2001).
35. D. Dankort, E. Filenova, M. Collado, M. Serrano, K. Jones, M. McMahon, A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev. 21, 379-384 (2007).
36. J. Jonkers, R. Meuwissen, H. van der Gulden, H. Peterse, M. van der Valk, A. Berns, Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29, 418-425 (2001).
37. S. Srinivas, T. Watanabe, C.-S. Lin, C. M. William, Y. Tanabe, T. M. Jessell, F. Costantini, Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev. Biol. 1, 4 (2001).
38. D. G. Kirsch, D. M. Dinulescu, J. B. Miller, J. Grimm, P. M. Santiago, N. P. Young, G. P. Nielsen, B. J. Quade, C. J. Chaber, C. P. Schultz, O. Takeuchi, R. T. Bronson, D. Crowley, S. J. Korsmeyer, S. S. Yoon, F. J. Hornicek, R. Weissleder, T. Jacks, A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat. Med. 13, 992-997 (2007).
39. Y. Huang, J. Yuan, E. Righi, W. S. Kamoun, M. Ancukiewicz, J.Nezivar, M. Santosuosso, J. D. Martin, M. R. Martin, F. Vianello, P. Leblanc, L. L. Munn, P. Huang, D. G. Duda, D. Fukumura, R. K. Jain, M. C. Poznansky, Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 109, 17561-17566 (2012).
40. E. I. Ager, S. V. Kozin, N. D. Kirkpatrick, G. Seano, D. P. Kodack, V. Askoxylakis, Y. Huang, S. Goel, M. Snuderl, A. Muzikansky, D. M. Finkelstein, D. T. Dransfield, L. Devy, Y. Boucher, D. Fukumura, R. K. Jain, Blockade of MMP14 activity in murine breast carcinomas: Implications for macrophages, vessels, and radiotherapy. J. Natl. Cancer Inst. 107, djv017 (2015).
41. J. Pharmacokinet. Pharmacodyn. 38, 653-669 (2011).